Alimentary Pharmabiotic Centre, Department of Medicine, University College Cork, Cork, Ireland.
Parkinsonism Relat Disord. 2012 Jun;18(5):433-40. doi: 10.1016/j.parkreldis.2011.12.004. Epub 2011 Dec 29.
Some of the gastrointestinal (GI) symptoms commonly experienced by patients with Parkinson's disease (PD) have been attributed to gastroparesis; however, the precise prevalence and relevance of gastric emptying delay in PD is unclear. The definition of gastroparesis varies; currently the most widely accepted definition (from the National Institute of Diabetes and Digestive and Kidney Diseases Gastroparesis Clinical Research Consortium) is the presence of appropriate symptoms (including nausea, retching, vomiting, stomach fullness, and inability to finish a meal) for ≥ 12 weeks, together with delayed gastric emptying on scintigraphy and the absence of any obstructive lesions on upper GI endoscopy. In PD patients, gastroparesis has the potential to affect nutrition and quality of life, as well as the absorption of PD medications, including L-dopa. This reduced absorption of L-dopa has implications for the control of the PD motor symptoms for which it is administered. We performed a systematic review of the literature on gastroparesis in PD with the aim of developing an evidence-based approach to its management. Based on this review, we conclude that while gastric emptying has been reported to be frequently delayed in PD, the existing data do not permit definitive conclusions concerning its true prevalence, relationship to the underlying disease process, relevance to PD management, or the optimal therapy of related GI symptoms. Further study of these important issues is, therefore, required.
一些常见的胃肠道（GI）症状，经历过帕金森病（PD）的患者已经归因于胃轻瘫;然而，胃排空延迟在 PD 中的精确患病率和相关性尚不清楚。胃轻瘫的定义各不相同;目前最广泛接受的定义（来自国家糖尿病、消化和肾脏病研究所胃轻瘫临床研究联盟）是存在适当的症状（包括恶心、呕吐、呕吐、胃部饱满和不能完成一顿饭）≥ 12 周，同时闪烁扫描显示胃排空延迟，上消化道内镜检查无任何梗阻性病变。在 PD 患者中，胃轻瘫有可能影响营养和生活质量，以及 PD 药物的吸收，包括左旋多巴。这种左旋多巴吸收减少对其用于治疗的 PD 运动症状的控制有影响。我们对 PD 胃轻瘫的文献进行了系统回顾，旨在为其治疗制定循证方法。基于这一回顾，我们得出的结论是，虽然已经报道 PD 中胃排空经常延迟，但现有数据不能明确得出其真正患病率、与潜在疾病过程的关系、对 PD 管理的相关性或相关 GI 症状的最佳治疗的结论。因此，需要进一步研究这些重要问题。
